Abstract Background/purpose: Currently, tigecycline-nonsusceptible Klebsiella pneumoniae (TNSKP) is mainly reported to emerge following clinical use of tigecycline and is usually polyclonal. This study aimed to characterize TNSKP isolated from patients without prior tigecycline use. Methods: Twenty-six TNSKP clinical isolates were collected, and carbapenemase and 16S rRNA methylase genes were identified by polymerase chain reaction and sequencing. Molecular typing was conducted by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Clinical data of patients in the carbapenem-susceptible TNSKP group and the tigecycline-and carbapenem-nonsusceptible K. pneumoniae (TCNSKP) group were compared. Results: Of the 26 TNSKP isolates, eight contained both bla KPC-2 and 16S rRNA methylase genes. In the remaining 18 TNSKP isolates, no carbapenemase gene was detected, and only three had the 16S rRNA methylase gene. Among the 26 isolates, 24 distinct pulsotypes and 19 sequence types (STs) were identified by PFGE and MLST, respectively. Six of the eight TCNSKP were ST11, whereas the remaining 18 TNSKP isolates were assigned to 17 different STs. exposure, mechanical ventilation, prior b-lactam/b-lactamase use, and longer hospitalization were more common for the TCNSKP group than for the carbapenem-susceptible TNSKP group. Conclusion: TNSKP can occur without tigecycline use, and TCNSKP ST11 is predominant among them. Further, this report proposes potential risk factors for the occurrence of carbapenemnonsusceptibility in TNSKP.
Introduction
Tigecycline, the first member of the glycylcyclines group of antibiotics with good in vitro activity against carbapenemresistant Klebsiella pneumoniae, 1,2 may provide a potential treatment option as a last resort defense against these "superbugs". While tigecycline-nonsusceptible rates among K. pneumoniae isolates are generally low, 3 tigecyclinenonsusceptible K. pneumoniae (TNSKP) has been reported to occur following clinical use of the antibiotic. 4e7 Data regarding the clinical features of TNSKP, as well as the microbiological and the molecular characteristics of TNSKP, remain scarce. Previously, we reported tigecycline resistance mechanisms for 26 TNSKP isolates, and that efflux pumps AcrAB and OqxAB played an essential role in tigecycline resistance in K. pneumoniae. 8 Although tigecycline has been available in China since the end of 2011, it is not commonly used in clinical practice because of its high price and limited indications for hospital-acquired infections. Herein, we report TNSKP infection or colonization in 26 patients who had not received tigecycline treatment previously and provide information concerning the predominance of ST11 among the tigecycline-and carbapenem-nonsusceptible K. pneumoniae (TCNSKP) isolates at Huashan Hospital in Shanghai, China. We also established the clinical and microbiological characteristics of the 26 TNSKP isolates, and investigated the factors that increase the risk of infection or colonization with TCNSKP.
Methods

Patients and isolates
Patients with TNSKP infection or colonization were identified among those admitted at Huashan Hospital, Fudan University, China. Only the first TNSKP was included in this study when more than one TNSKP isolate was isolated from the same patient. Twenty-six nonduplicated TNSKP isolates were identified during a study investigating tigecycline resistance mechanisms in Enterobacteriaceae.
8 Minimum inhibitory concentrations (MICs) of other antimicrobial agents were determined by the agar dilution methodology and interpreted following the recommendations of the Clinical and Laboratory Standards Institute (CLSI, Wayne, PA, USA). 9 Escherichia coli ATCC 25922 was used as the quality control strain.
Detection of b-lactamase and 16S rRNA methylase genes
All TNSKP were tested for the presence of various carbapenemase genes (bla KPC , bla NDM , bla IMP , bla VIM , bla SPM , and bla SIM ) and 16S rRNA methylase genes (armA and rmtB) by polymerase chain reaction and sequencing as described previously.
10,11
Molecular typing
Pulsed-field gel electrophoresis (PFGE) was performed to determine genetic relatedness of the isolates using the restriction enzyme XbaI (TaKaRa Biotechnology Co. Ltd., Dalian, China). Multilocus sequence typing (MLST) was carried out as described earlier. 12 The PFGE banding patterns were compared via the BioNumerics version 6.6 software (Applied Maths, Sint-Martens-Latem, Belgium), and a similarity cutoff of 90% was used. 13 
Clinical data collection
Clinical information, including demographic data, duration of hospital stay, day of specimen collection, location of the patient, healthcare exposure within the prior 6 months, device use at the time of TNSKP isolation, utilization of antimicrobial agents prior to TNSKP isolation after the admission, underlying diseases, and outcomes (died or alive during hospital stay), were collected. The time of the TNSKP isolation was defined as the day of collection of the specimen in which TNSKP bacteria were detected.
Statistical analysis
Contingency data were analyzed by the Fisher's exact test, and continuous data were assessed by the Student t test. A p value < 0.05 was considered as statistically significant, and the odds ratio was calculated with confidence intervals of 95% (95% CI). Statistical analyses were carried out using SPSS 19.0 (SSPS Inc., Chicago, IL, USA).
Results
Of the 26 TNSKP isolates, eight (30.8%) were TCNSKP (meropenem MICs, 16e128 mg/mL; imipenem MICs, 4e128 mg/ mL). These eight TCNSKP isolates were resistant to all antimicrobial agents tested except to colistin (MICs, 0.25e1 mg/ mL), and four were susceptible to fosfomycin. The remaining 18 TNSKP isolates were susceptible to meropenem, imipenem, fosfomycin, and colistin, and had a high rate of susceptibility to piperacillin/tazobactam (83.3%), aztreonam (72.2%), and cefepime (88.9%; Table 1 ). The most common sources of isolation were urine (n Z 13), followed by sputum (n Z 8), bile (n Z 4), and blood (n Z 1; Figure 1 ).
Of the 26 TNSKP isolates, the eight TCNSKP isolates carried bla KPC-2 and also harbored a 16S rRNA methylase gene (armA, n Z 2 and rmtB, n Z 6) in accordance with their aminoglycoside resistance phenotype. In the remaining 18 carbapenem-susceptible TNSKP isolates, polymerase chain reaction was negative for the carbapenemase genes tested, and only three possessed a 16S rRNA methylase gene (rmtB, n Z 2 and armA, n Z 1).
The 26 TNSKP isolates were assigned to 24 distinct pulsotypes and 19 distinct sequence types (STs; Figure 1 ), among which ST11 was the predominant ST type (n Z 7, 26.9%), followed by ST37 (n Z 2). Of the eight TCNSKP isolates, six were ST11, while the other two were ST690 (a single-locus variant of ST11) and ST39. Among the remaining 18 carbapenem-susceptible TNSKP isolates, 17 STs were identified, including three new STs designated in this study as STn1, STn2, and STn3, respectively ( Figure 1 ).
Of the 26 patients with TNSKP, two outpatients were excluded since their clinical records were not available. Thus, the clinical data of the 24 patients were collected and grouped based on the TNSKP with carbapenemresistance (TCNSKP group) or not (carbapenem-susceptible TNSKP group; Table 2) .
Overall, 31 different antibiotics were administered after admission, prior to the isolation of TNSKP from the 26 patients, including b-lactams/b-lactamase inhibitors, fluoroquinolones, carbapenems, and cephalosporins. However, tigecycline was not given to any patient before TNSKP isolation.
Seven (87.5%) of the eight patients with TCNSKP had a history of intensive care unit (ICU) stay, whereas three (18.8%) patients in the carbapenem-susceptible TNSKP group had a history of ICU stay (p < 0.01; odds ratio, 30.33; 95% CI, 2.64e348.96; Table 3 ). Mechanical ventilation and b-lactam/b-lactamase inhibitors use were also significantly more common in the TCNSKP group (both p Z 0.02). Moreover, the mean interval between patient admission to this hospital and the isolation of TNSKP was 36 days (range, 7e72 d) in the TCNSKP group and 16 days (range, 0e70 d) in the TNSKP group (p Z 0.01), suggesting that longer hospitalization likely contributes to the isolation of TCNSKP. Tigecycline minimum inhibitory concentrations (MICs) were determined by the broth microdilution method, and others were determined by the agar dilution method. AMK Z amikacin; COL Z colistin; CTX Z cefotaxime; FEP Z cefepine; FOS Z fosfomycin; IPM Z imipenem; LEV Z levofloxacin; MEM Z meropenem; MIC Z minimum inhibitory concentration; MIN Z minocycline; TGC Z tigecycline; TNSKP Z tigecycline-nonsusceptible Klebsiella pneumoniae; TZP Z piperacillin-tazobactam.
Discussion
In the present study, tigecycline was not prescribed to any patient prior to TNSKP isolation, which was contrary to findings of a nested case-control study which revealed the receipt of tigecycline as the only independent predictor of subsequent isolation of a tigecycline-resistant K. pneumoniae isolate. 14 We hypothesized that spontaneous mutations or the use of other types of antibiotics might have contributed to the emergence of TNSKP in this examination. It is also possible that TNSKP existed and was disseminated by other patients who had been treated with tigecycline, although it is not commonly used in China.
Lin et al 15 reported that no major cluster of 36 TNSKP isolates was identified by PFGE, which was consistent with the results of our study. However, in the present investigation, MLST indicated predominance of ST11 among the TNSKP isolates, in particular TCNSKP isolates (6/8, 75.0%). Zhong et al 16 also established that K. pneumoniae ST11 was the predominant lineage among tigecycline-and carbapenemnonsusceptible isolates. These findings indicated that ST11 exerts an important role in TNSKP, especially TCNSKP.
ST11 is the most common ST among K. pneumoniae carbapenemase (KPC)-2-producing K. pneumoniae in China 17 and some other regions. 18e21 This international epidemic of the K. pneumoniae ST11 clone may suggest the presence of selective advantages that facilitate the spread of carbapenem-resistance among TNSKP isolates. Therefore, TCNSKP ST11 may have the potential to be extensively disseminated. Tigecycline and polymyxin are usually recommended as last resort agents for the treatment of multidrug-resistant and/or extensively drug-resistant Gram-negative bacilli such as KPC-producing K. pneumoniae. Therefore, the emergence of TCNSKP is a real threat, especially for those regions and countries (such as China) where polymyxins are not available for clinical use.
Approaches to control the dissemination of TCNSKP are urgent. Based on the guidelines for multidrug-resistant Gram-negative bacteria, 22 we suggest: (1) measures such as enhanced antimicrobial stewardship and infection control compliance are needed to avoid the emergence and even outbreak of TCNSKP; (2) efforts such as reinforcement of hand hygiene and decolonization are important to reduce the spread of TCNSKP; and (3) active surveillance cultures should be performed in patients predisposed by the conditions mentioned above. In addition, routine microbiologic surveillance of newly admitted patients and outpatients may be not recommended, Figure 1 . Pulsed-field gel electrophoresis (PFGE) dendrogram of 26 tigecycline-nonsusceptible Klebsiella pneumoniae (TNSKP) analyzed by BioNumerics, and the corresponding sequence types (STs) of the isolates. A similarity cutoff of 90% was used to group TNSKP (red dotted line). TNSKP with carbapenem resistance was indicated (red rectangle). ICU Z intensive care unit; ST Z sequence type.
because the rate of TNSKP and TCNSKP isolation is very low in K. pneumoniae.
8
Of note, TNSKP10 (ST11) and TNSKP19 (ST37) isolates were from outpatients. Although TNSKP isolates may naturally exist in the community, we cannot rule out the possibility that these two are hospital-associated TNSKP, as the outpatients may have a history of hospitalization and then colonization by TNSKP. Actually, K. pneumoniae ST11 and ST37 have played an essential role in transfer and even nosocomial outbreak of carbapenem resistance (conferred by bla KPC and bla NDM respectively), which leads us to suspect that TNSKP with these two STs may disseminate in the community.
In conclusion, here we report the identification of TNSKP in 26 specimens isolated from patients without prior exposure to tigecycline, and the emergence of TCNSKP ST11 as the predominant clone in TNSKP. In addition, ICU exposure, mechanical ventilation, use of blactam/b-lactamase inhibitors, and longer hospitalization were established as possibly associated with the occurrence of carbapenem-nonsusceptibility in clinical TNSKP. ICU Z intensive care unit; CI Z confidence intervals; TCNSKP Z tigecycline-and carbapenem-nonsusceptible K. pneumoniae; TNSKP Z tigecycline-nonsusceptible K. pneumoniae.
